Trials / Unknown
UnknownNCT05784779
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)/Non-alcoholic Fatty Liver Disease (NAFLD)
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- 1Globe Biomedical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase Ib/II, randomized, double-blind, placebo-controlled, international multi-center clinical study to investigate the efficacy and safety of GH509 in subjects with NASH/NAFLD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GH509 | Orally, once daily before bedtime (qhs) |
| DRUG | Placebo | Orally, once daily before bedtime (qhs) |
Timeline
- Start date
- 2023-02-28
- Primary completion
- 2024-05-28
- Completion
- 2024-06-28
- First posted
- 2023-03-27
- Last updated
- 2023-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05784779. Inclusion in this directory is not an endorsement.